MustGrow Biologics President & CEO Corey Giasson joins Natalie Stoberman from the Proactive newsrooms to share the company's successful completion of initial commercial run-rate production via third-party contract manufacturer for its mustard plant-based extract.
Giasson says this production milestone demonstrates the scalability of its product process along with positioning the company for future sales and commercialization. Giasson adds that this milestone validates MustGrow's strategy and reducing the need for significant upfront investment to begin the mass commercialization process. He adds that using a third-party manufacturer enables a low risk and scalable foundation for their production process.